Assessing the gold standard - Lessons from the history of RCTs

New England Journal of Medicine

Volumn 374, Issue 22, 2016, Pages 2175-2181

  Bothwell, Laura E ^a,b   Greene, Jeremy A ^d   Podolsky, Scott H ^b   Jones, David S ^b,c   Malina, Debra ^e  

^a Division of Pharmacoepidemiology and Pharmacoeconomics   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROLEPTIC AGENT; THALIDOMIDE; THIAZIDE DIURETIC AGENT;

ANGINA PECTORIS; ARTERY LIGATION; ARTHROSCOPIC DEBRIDEMENT; ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; CASE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DECISION MAKING; DRUG ELUTING STENT; ELECTRONIC MEDICAL RECORD; EXTERNAL VALIDITY; FEASIBILITY STUDY; GOLD STANDARD; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INTERNAL MAMMARY ARTERY LIGATION; INTERVENTION STUDY; KNEE OSTEOARTHRITIS; OBSERVATIONAL STUDY; PATIENT CARE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; ETHICS; FEMALE; HISTORY; LEGISLATION AND JURISPRUDENCE; PREGNANCY; STATISTICS AND NUMERICAL DATA;

DRUG APPROVAL; DRUG INDUSTRY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEGISLATION, DRUG; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84973309295     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMms1604593     Document Type: Article

References (59)

1. Opinel A, Tröhler U, Gluud C, et al. Commentary: the evolution of methods to assess the effects of treatments, illustrated by the development of treatments for diphtheria, 1825-1918. Int J Epidemiol 2013; 42: 662-76.
2. Podolsky SH, Jones DS, Kaptchuk TJ. From trials to trials: blinding, medicine, and honest adjudication. In: Robertson CT, Kesselheim AS, eds. Blinding as a solution to bias: strengthening biomedical science, forensic science, and law. Amsterdam: Elsevier, 2016: 45-58.
3. Bothwell L. The emergence of the randomized controlled trial: origins to 1980 (Ph.D. dissertation). New York: Columbia University Academic Commons, 2014.
4. Hill AB Medical ethics and controlled trials. Br Med J 1963; 1: 1043-9.
5. Podolsky SH The antibiotic era: reform, resistance, and the pursuit of a rational therapeutics. Baltimore: Johns Hopkins University Press, 2015.
6. Goodman J. Pharmaceutical industry. In: Cooter R, Pickstone J V, eds. Companion to medicine in the twentieth century. New York: Taylor and Francis, 2000: 150.
7. Antibiotic combinations. N Engl J Med 1956; 255: 1057-9.
8. Greene JA, Podolsky SH. Reform, regulation, and pharmaceuticals - the Kefauver-Harris Amendments at 50. N Engl J Med 2012; 367: 1481-3.
9. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton, NJ: Princeton University Press, 2010.
10. Kuo W-H. Japan and Taiwan in the wake of bio-globalization: drugs, race and standards (Ph.D. dissertation). Cambridge: Massachusetts Institute of Technology, 2005.
11. Daly J. Evidence-based medicine and the search for a science of clinical care. Berkeley: University of California Press, 2005.
12. Timmermans S, Berg M. The gold standard: the challenge of evidence-based medicine and standardization in health care. Philadelphia: Temple University Press, 2003.
13. Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet 2015; 385: 1502-3.
14. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371: 1418-25.
15. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015; 372: 2423-7.
16. Brasil P, Pereira JP Jr, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report. N Engl J Med. doi: 10.1056/NEJMoa1602412.
17. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-37.
18. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-56.
19. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1: 263.
20. Seligman MEP. The effectiveness of psychotherapy: the Consumer Reports study. Am Psychol 1995; 50: 965-74.
21. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-82.
22. Ablon JS, Jones EE. Validity of controlled clinical trials of psychotherapy: findings from the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 2002; 159: 775-83.
23. Deacon BJ The biomedical model of mental disorder: a critical analysis of its validity, utility, and effects on psychotherapy research. Clin Psychol Rev 2013; 33: 846-61.
24. Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA. An evaluation of internal-mammary-artery ligation by a doubleblind technic. N Engl J Med 1959; 260: 1115-8.
25. Love J W. Drugs and operations: some important differences. JAMA 1975; 232: 37-8.
26. Murphy ML, Hultgren HN, Detre K, Thomsen J, Takaro T, Participants of the Veterans Administration Cooperative Study. Treatment of chronic stable angina - a preliminary report of survival data of the randomized Veterans Administration cooperative study. N Engl J Med 1977; 297: 621-7.
27. Braunwald E. Coronary-artery surgery at the crossroads. N Engl J Med 1977; 297: 661-3.
28. Jones DS Visions of a cure: visualization, clinical trials, and controversies in cardiac therapeutics, 1968-1998. Isis 2000; 91: 504-41.
29. Special correspondence: a debate on coronary bypass. N Engl J Med 1977; 297: 1464-70.
30. Bonchek LI Are randomized trials appropriate for evaluating new operations? N Engl J Med 1979; 301: 44-5.
31. Favaloro RG Critical analysis of coronary artery bypass graft surgery: a 30-year journey. J Am Coll Cardiol 1998; 31: Suppl: 1B-63B.
32. Ullyot DJ, Wisneski J, Sullivan RW, Gertz EW. Reply to: The controversy over coronary arterial surgery: inappropriate controls, inappropriate publicity. J Thorac Cardiovasc Surg 1976; 72: 945.
33. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-16.
34. Kereiakes DJ, Teirstein PS, Sarembock IJ, et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol 2007; 50: 1598-603.
35. Jones DS Therapeutic evolution or revolution? Metaphors and their consequences. In: Greene JA, Condrau F, Watkins ES, eds. Therapeutic revolutions: pharmaceuticals and social change in the twentieth century. Chicago: University of Chicago Press, 2016.
36. Marks HM The progress of experiment: science and therapeutic reform in the United States, 1900-1990. Cambridge, United Kingdom: Cambridge University Press, 1997.
37. Greene JA Prescribing by numbers: drugs and the definition of disease. Baltimore: Johns Hopkins University Press, 2007.
38. Pollack A. The minimal impact of a big hypertension study. New York Times. November 27, 2008: B1.
39. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-8.
40. Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms. Br J Sports Med 2015; 49: 1229-35.
41. Epstein S. Impure science: AIDS, activism, and the politics of knowledge. Berkeley: University of California Press, 1996.
42. Hellman S, Hellman DS. Of mice but not men - problems of the randomized clinical trial. N Engl J Med 1991; 324: 1585-9.
43. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997; 337: 853-6.
44. Rothman DJ The shame of medical research. New York Rev Books 2000; 47(19): 60-4.
45. Angell M. The ethics of clinical research in the Third World. N Engl J Med 1997; 337: 847-9.
46. Epstein S. Activism, drug regulation, and the politics of therapeutic evaluation in the AIDS era: a case study of ddC and the 'surrogate markers' debate. Soc Stud Sci 1997; 27: 691-726.
47. Sertkaya A, Birkenbach A, Berlind A, Eyraud J. Examination of clinical trial costs and barriers for drug development: report to the Assistant Secretary of Planning and Evaluation (ASPE). Washington, DC: Department of Health and Human Services, July 25, 2014.
48. Petryna A. When experiments travel: clinical trials and the global search for human subjects. Princeton, NJ: Princeton University Press, 2009.
49. Scannell J. Four reasons drugs are expensive, of which two are false. Forbes.com. October 13, 2015 (http://www.forbes.com/sites/matthewherper/2015/10/13/four-reasons-drugs-are-expensive-of-which-two-are-false).
50. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010; 153: 158-66.
51. Burdett S, Stewart LA, Tierney JF. Publication bias and meta-analyses: a practical example. Int J Technol Assess Health Care 2003; 19: 129-34.
52. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA 2007; 297: 2112-20.
53. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 2003; 78: 769-74.
54. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539-44.
55. Fisher JA, Kalbaugh CA. United States private-sector physicians and pharmaceutical contract research: a qualitative study. PLoS Med 2012; 9(7): e1001271.
56. Baicker K, Taubman SL, Allen HL, et al. The Oregon experiment - effects of Medicaid on clinical outcomes. N Engl J Med 2013; 368: 1713-22.
57. The World Bank is finally embracing science. Lancet 2004; 364: 731-2.
58. Deaton A. Instruments, randomization, and learning about development. J Econ Lit 2010; 48: 424-55.
59. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A. Knopf, 2004.